search
Back to results

Clinical Trial of Vit D and Calcium for Recurrent BPPV

Primary Purpose

BPPV, Benign Paroxysmal Positional Vertigo, Vertigo

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
vitamin D +/- calcium
Placebo
Sponsored by
Ottawa Hospital Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for BPPV focused on measuring bppv, benign paroxysmal positional vertigo, vertigo, dizziness, vitamin D

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age 18 years or older 2 or more distinct episodes of benign paroxysmal positional vertigo within a 12-month period on history At least 1 episode diagnosed based on physical examination by trained study personnel, meeting the diagnostic criteria of the Bárány Society Episodes separated in time, with a minimum of 1 week symptom-free between episodes Serum evidence of Vitamin D deficiency, as evidenced by 25-hydroxy vitamin D level of <75 nmol/L (<30 ng/mL)48 Subject able to provide informed consent to participate in the study Exclusion Criteria: Potential subjects will be excluded if they have another identifiable cause of vertigo identified on history or physical examination have a history of allergy or medically significant adverse reaction to vitamin D or calcium carbonate have a chronic medical disorder which is a contraindication to vitamin D or calcium carbonate supplementation, including uncontrolled hyperparathyroidism, nephrolithiasis, or GI malabsorption disorders are on loop diuretic agents or thiazides have a contraindication to routine bloodwork for study purposes, including being hospitalized with a critical illness, cellulitis at blood draw sites, or presence of vascular grafts.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    vitamin D +/- calcium supplementation

    Placebo arm

    Arm Description

    patients given Vitamin D 1000iu daily. Also given calcium 500mg BID daily if calcium deficient.

    patients given 3 pills of placebo daily.

    Outcomes

    Primary Outcome Measures

    Recurrence rate of BPPV
    how many recurrences of BPPV

    Secondary Outcome Measures

    serum vitamin D levels (25(OH)D3)
    serum vitamin D levels
    proportion of serum vitamin D normalization
    do patients normalize
    time to serum vitamin D normalization
    how long does it take patients to normalize
    proportion of recurrences
    what proportion of total patients have recurrences
    duration of recurrences
    how long do recurrences of BPPV last
    EQ-5D
    quality of life measurement
    days per year of missed school/work
    days per year of missed school/work

    Full Information

    First Posted
    April 28, 2023
    Last Updated
    May 8, 2023
    Sponsor
    Ottawa Hospital Research Institute
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05863949
    Brief Title
    Clinical Trial of Vit D and Calcium for Recurrent BPPV
    Official Title
    STOP Vertigo: Supplementation of Vitamin D for Termination of Recurrences From Benign Paroxysmal Positional Vertigo
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    July 2023 (Anticipated)
    Primary Completion Date
    July 2024 (Anticipated)
    Study Completion Date
    July 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Ottawa Hospital Research Institute

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Randomized double blind placebo controlled trial of vitamin D supplements, with or without calcium supplementation, versus placebo in reduction of recurrences in BPPV.
    Detailed Description
    Benign paroxysmal positional vertigo (BPPV) is the most common neuro-otological disorder, with a lifetime prevalence of 2.4 percent.1 BPPV is responsible for nearly one-half of cases of peripheral vestibular dysfunction. It is a highly recurrent disorder, with more than 1 in 4 patients experiencing a second attack, often within 6 months of the first.2-4 According to the Clinical Practice Guidelines for BPPV from the American Academy of Otolaryngology-Head and Neck Surgery Foundation, particle repositioning maneuvers (PRMs) are the only recommended treatment to resolve symptoms for both initial BPPV episodes as well as persistent episodes.5 While attacks can be effectively treated by PRMs, these often must be performed by a physician or other trained healthcare professional, and sometimes multiple attempts are required in order to successfully resolve a patient's symptoms. Furthermore, even with effective particle repositioning, a subset of patients may continue to experience bouts of recurrent attacks, up to several times yearly. The attacks themselves, as well as the nature of their treatment, - especially in patients with recurrent episodes - are prone to lead to interruptions in patients' daily activities, cause sick leaves, and result in significant direct and indirect costs to both the patient and the healthcare system.6 The prevalence of BPPV increases with age and elderly patients with BPPV are more likely to have reduced activities of daily living (ADL) scores, sustain falls, and suffer from depression.4,7 In the United States (US), more than sixty-five percent of patients with BPPV experience potentially avoidable diagnostic testing or therapeutic interventions during the time leading up to a proper diagnosis, costing the US health care system nearly $2 billion per year.5 BPPV is widely accepted to be caused by otoconia that are dislodged from the utricular macula into the semicircular canals - most commonly the posterior canal.8 Otoconia are made of a largely organic core of glycoproteins, with a predominantly inorganic periphery of calcium carbonate.9 Otoconia form within the otherwise low-calcium endolymph via an active, tightly controlled and ordered process.10 Recent studies have shown that the biomineralization of otoconia has similarities to that of bone and teeth, and that bone metabolism has a connection to BPPV. 11-13 Furthermore, an association has been demonstrated between BPPV and osteoporosis, and otoconia formation has been shown to be dysfunctional in animal models of osteoporosis.14,15 The impact of recurrent BPPV on both patients and the healthcare system is multiplicative. With each episode of recurrence, patients become symptomatic - potentially severely so - and must seek treatment again in the form of particle repositioning maneuvers. These patients therefore suffer further functional impairment, potentially missed school and work, and require healthcare interventions which are not without cost to the system. No preventative treatment option for recurrent BPPV exists. Establishing such a preventative treatment would have significant implications in reducing both direct and indirect costs of this highly prevalent and recurrent disorder. Vitamin D is involved in bodily calcium regulation, and thus poses an attractive potential treatment for BPPV. Vitamin D deficiency is common in many regions worldwide, and supplementation carries little risk. A body of literature has emerged to date investigating potential links between vitamin D deficiency and BPPV - especially recurrent - and whether vitamin D supplementation could in turn serve some role in treatment or prevention.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    BPPV, Benign Paroxysmal Positional Vertigo, Vertigo, Vertigo, Peripheral, Dizziness, Dizziness; Epidemic, Vitamin D Deficiency, Calcium Deficiency
    Keywords
    bppv, benign paroxysmal positional vertigo, vertigo, dizziness, vitamin D

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    This is an off-label, multicenter, randomized, clinical trial in vitamin D deficient adults aged 18 and above with recurrent BPPV. Its goal is to determine whether vitamin D supplementation, with or without calcium supplementation, compared with placebo will decrease the frequency of recurrent episodes of BPPV. A total of 860 vitamin D deficient adults diagnosed with recurrent BPPV will be enrolled at participating clinical study sites.
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Masking Description
    Enrolled subjects will be blinded to their treatment assignment. Both study staff and trial investigators will be blinded to treatment assignments and will remain blinded throughout the course of the trial. Randomization (treatment assignment) will be performed via computer algorithm based on subject ID. Randomization codes will be maintained in a password protected, encrypted file available only to the single unmasked investigator at each site, in order to prevent accidental unmasking of other trial personnel. All care will be taken to ensure that the study team are kept blinded. Pills, which will be dispensed at 3-month intervals, will be indistinguishable between groups. They will be dispensed in kits that are labeled as outlined in section 6.2 Study Drug Packaging and Labeling.
    Allocation
    Randomized
    Enrollment
    860 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    vitamin D +/- calcium supplementation
    Arm Type
    Experimental
    Arm Description
    patients given Vitamin D 1000iu daily. Also given calcium 500mg BID daily if calcium deficient.
    Arm Title
    Placebo arm
    Arm Type
    Placebo Comparator
    Arm Description
    patients given 3 pills of placebo daily.
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    vitamin D +/- calcium
    Intervention Description
    vitamin D 1000iU daily +/- calcium 500mg BID daily
    Intervention Type
    Other
    Intervention Name(s)
    Placebo
    Intervention Description
    placebo pill x3 daily
    Primary Outcome Measure Information:
    Title
    Recurrence rate of BPPV
    Description
    how many recurrences of BPPV
    Time Frame
    1 year
    Secondary Outcome Measure Information:
    Title
    serum vitamin D levels (25(OH)D3)
    Description
    serum vitamin D levels
    Time Frame
    1 year
    Title
    proportion of serum vitamin D normalization
    Description
    do patients normalize
    Time Frame
    1 year
    Title
    time to serum vitamin D normalization
    Description
    how long does it take patients to normalize
    Time Frame
    1 year
    Title
    proportion of recurrences
    Description
    what proportion of total patients have recurrences
    Time Frame
    1 year
    Title
    duration of recurrences
    Description
    how long do recurrences of BPPV last
    Time Frame
    1 year
    Title
    EQ-5D
    Description
    quality of life measurement
    Time Frame
    1 year
    Title
    days per year of missed school/work
    Description
    days per year of missed school/work
    Time Frame
    1 year

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age 18 years or older 2 or more distinct episodes of benign paroxysmal positional vertigo within a 12-month period on history At least 1 episode diagnosed based on physical examination by trained study personnel, meeting the diagnostic criteria of the Bárány Society Episodes separated in time, with a minimum of 1 week symptom-free between episodes Serum evidence of Vitamin D deficiency, as evidenced by 25-hydroxy vitamin D level of <75 nmol/L (<30 ng/mL)48 Subject able to provide informed consent to participate in the study Exclusion Criteria: Potential subjects will be excluded if they have another identifiable cause of vertigo identified on history or physical examination have a history of allergy or medically significant adverse reaction to vitamin D or calcium carbonate have a chronic medical disorder which is a contraindication to vitamin D or calcium carbonate supplementation, including uncontrolled hyperparathyroidism, nephrolithiasis, or GI malabsorption disorders are on loop diuretic agents or thiazides have a contraindication to routine bloodwork for study purposes, including being hospitalized with a critical illness, cellulitis at blood draw sites, or presence of vascular grafts.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Darren Tse, MD
    Phone
    6137997838
    Ext
    13360
    Email
    dtse88@gmail.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Darren Tse
    Phone
    6137997838
    Email
    dtse88@gmail.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Darren Tse, MD
    Organizational Affiliation
    Ottawa Hospita Research Institute
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    26756126
    Citation
    von Brevern M, Bertholon P, Brandt T, Fife T, Imai T, Nuti D, Newman-Toker D. Benign paroxysmal positional vertigo: Diagnostic criteria. J Vestib Res. 2015;25(3-4):105-17. doi: 10.3233/VES-150553.
    Results Reference
    background
    PubMed Identifier
    29649052
    Citation
    Luryi AL, Lawrence J, Bojrab DI, LaRouere M, Babu S, Zappia J, Sargent EW, Chan E, Naumann I, Hong RS, Schutt CA. Recurrence in Benign Paroxysmal Positional Vertigo: A Large, Single-Institution Study. Otol Neurotol. 2018 Jun;39(5):622-627. doi: 10.1097/MAO.0000000000001800.
    Results Reference
    background
    PubMed Identifier
    22388730
    Citation
    Perez P, Franco V, Cuesta P, Aldama P, Alvarez MJ, Mendez JC. Recurrence of benign paroxysmal positional vertigo. Otol Neurotol. 2012 Apr;33(3):437-43. doi: 10.1097/MAO.0b013e3182487f78.
    Results Reference
    background
    PubMed Identifier
    31798518
    Citation
    Zhu CT, Zhao XQ, Ju Y, Wang Y, Chen MM, Cui Y. Clinical Characteristics and Risk Factors for the Recurrence of Benign Paroxysmal Positional Vertigo. Front Neurol. 2019 Nov 13;10:1190. doi: 10.3389/fneur.2019.01190. eCollection 2019.
    Results Reference
    background
    PubMed Identifier
    28248609
    Citation
    Bhattacharyya N, Gubbels SP, Schwartz SR, Edlow JA, El-Kashlan H, Fife T, Holmberg JM, Mahoney K, Hollingsworth DB, Roberts R, Seidman MD, Steiner RW, Do BT, Voelker CC, Waguespack RW, Corrigan MD. Clinical Practice Guideline: Benign Paroxysmal Positional Vertigo (Update). Otolaryngol Head Neck Surg. 2017 Mar;156(3_suppl):S1-S47. doi: 10.1177/0194599816689667.
    Results Reference
    background
    PubMed Identifier
    17135456
    Citation
    von Brevern M, Radtke A, Lezius F, Feldmann M, Ziese T, Lempert T, Neuhauser H. Epidemiology of benign paroxysmal positional vertigo: a population based study. J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):710-5. doi: 10.1136/jnnp.2006.100420. Epub 2006 Nov 29.
    Results Reference
    background
    PubMed Identifier
    10793337
    Citation
    Oghalai JS, Manolidis S, Barth JL, Stewart MG, Jenkins HA. Unrecognized benign paroxysmal positional vertigo in elderly patients. Otolaryngol Head Neck Surg. 2000 May;122(5):630-4. doi: 10.1016/S0194-5998(00)70187-2.
    Results Reference
    background
    PubMed Identifier
    14517129
    Citation
    Parnes LS, Agrawal SK, Atlas J. Diagnosis and management of benign paroxysmal positional vertigo (BPPV). CMAJ. 2003 Sep 30;169(7):681-93.
    Results Reference
    background
    PubMed Identifier
    10945971
    Citation
    Lins U, Farina M, Kurc M, Riordan G, Thalmann R, Thalmann I, Kachar B. The otoconia of the guinea pig utricle: internal structure, surface exposure, and interactions with the filament matrix. J Struct Biol. 2000 Jul;131(1):67-78. doi: 10.1006/jsbi.2000.4260.
    Results Reference
    background
    PubMed Identifier
    16600187
    Citation
    Lundberg YW, Zhao X, Yamoah EN. Assembly of the otoconia complex to the macular sensory epithelium of the vestibule. Brain Res. 2006 May 26;1091(1):47-57. doi: 10.1016/j.brainres.2006.02.083. Epub 2006 Apr 4.
    Results Reference
    background
    PubMed Identifier
    17300776
    Citation
    Zhao X, Yang H, Yamoah EN, Lundberg YW. Gene targeting reveals the role of Oc90 as the essential organizer of the otoconial organic matrix. Dev Biol. 2007 Apr 15;304(2):508-24. doi: 10.1016/j.ydbio.2007.01.013. Epub 2007 Jan 12.
    Results Reference
    background
    PubMed Identifier
    20803598
    Citation
    Xu Y, Zhang H, Yang H, Zhao X, Lovas S, Lundberg YW. Expression, functional, and structural analysis of proteins critical for otoconia development. Dev Dyn. 2010 Oct;239(10):2659-73. doi: 10.1002/dvdy.22405. Erratum In: Dev Dyn. 2011 Feb;240(2):457.
    Results Reference
    background
    PubMed Identifier
    19307540
    Citation
    Jeong SH, Choi SH, Kim JY, Koo JW, Kim HJ, Kim JS. Osteopenia and osteoporosis in idiopathic benign positional vertigo. Neurology. 2009 Mar 24;72(12):1069-76. doi: 10.1212/01.wnl.0000345016.33983.e0.
    Results Reference
    background
    PubMed Identifier
    14587980
    Citation
    Vibert D, Kompis M, Hausler R. Benign paroxysmal positional vertigo in older women may be related to osteoporosis and osteopenia. Ann Otol Rhinol Laryngol. 2003 Oct;112(10):885-9. doi: 10.1177/000348940311201010.
    Results Reference
    background
    PubMed Identifier
    18391565
    Citation
    Vibert D, Sans A, Kompis M, Travo C, Muhlbauer RC, Tschudi I, Boukhaddaoui H, Hausler R. Ultrastructural changes in otoconia of osteoporotic rats. Audiol Neurootol. 2008;13(5):293-301. doi: 10.1159/000124277. Epub 2008 Apr 7.
    Results Reference
    background
    PubMed Identifier
    31630244
    Citation
    Yang B, Lu Y, Xing D, Zhong W, Tang Q, Liu J, Yang X. Association between serum vitamin D levels and benign paroxysmal positional vertigo: a systematic review and meta-analysis of observational studies. Eur Arch Otorhinolaryngol. 2020 Jan;277(1):169-177. doi: 10.1007/s00405-019-05694-0. Epub 2019 Oct 19.
    Results Reference
    background
    PubMed Identifier
    32767116
    Citation
    Jeong SH, Lee SU, Kim JS. Prevention of recurrent benign paroxysmal positional vertigo with vitamin D supplementation: a meta-analysis. J Neurol. 2022 Feb;269(2):619-626. doi: 10.1007/s00415-020-09952-8. Epub 2020 Aug 7.
    Results Reference
    background
    PubMed Identifier
    23245911
    Citation
    Buki B, Ecker M, Junger H, Lundberg YW. Vitamin D deficiency and benign paroxysmal positioning vertigo. Med Hypotheses. 2013 Feb;80(2):201-4. doi: 10.1016/j.mehy.2012.11.029. Epub 2012 Dec 14.
    Results Reference
    background
    PubMed Identifier
    27386060
    Citation
    Sheikhzadeh M, Lotfi Y, Mousavi A, Heidari B, Monadi M, Bakhshi E. Influence of supplemental vitamin D on intensity of benign paroxysmal positional vertigo: A longitudinal clinical study. Caspian J Intern Med. 2016 Spring;7(2):93-8.
    Results Reference
    background
    PubMed Identifier
    26386496
    Citation
    Talaat HS, Kabel AM, Khaliel LH, Abuhadied G, El-Naga HA, Talaat AS. Reduction of recurrence rate of benign paroxysmal positional vertigo by treatment of severe vitamin D deficiency. Auris Nasus Larynx. 2016 Jun;43(3):237-41. doi: 10.1016/j.anl.2015.08.009. Epub 2015 Sep 16.
    Results Reference
    background
    PubMed Identifier
    32759193
    Citation
    Jeong SH, Kim JS, Kim HJ, Choi JY, Koo JW, Choi KD, Park JY, Lee SH, Choi SY, Oh SY, Yang TH, Park JH, Jung I, Ahn S, Kim S. Prevention of benign paroxysmal positional vertigo with vitamin D supplementation: A randomized trial. Neurology. 2020 Sep 1;95(9):e1117-e1125. doi: 10.1212/WNL.0000000000010343. Epub 2020 Aug 5.
    Results Reference
    background
    PubMed Identifier
    27733354
    Citation
    Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hrobjartsson A, Kirkham J, Juni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schunemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12;355:i4919. doi: 10.1136/bmj.i4919.
    Results Reference
    background
    PubMed Identifier
    19543765
    Citation
    Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, El-Hajj Fuleihan G, Josse RG, Lips P, Morales-Torres J; IOF Committee of Scientific Advisors (CSA) Nutrition Working Group. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009 Nov;20(11):1807-20. doi: 10.1007/s00198-009-0954-6. Epub 2009 Jun 19. Erratum In: Osteoporos Int. 2009 Nov;20(11):1821.
    Results Reference
    background
    PubMed Identifier
    18458986
    Citation
    Hagenau T, Vest R, Gissel TN, Poulsen CS, Erlandsen M, Mosekilde L, Vestergaard P. Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos Int. 2009 Jan;20(1):133-40. doi: 10.1007/s00198-008-0626-y. Epub 2008 May 6.
    Results Reference
    background
    PubMed Identifier
    30087817
    Citation
    Parva NR, Tadepalli S, Singh P, Qian A, Joshi R, Kandala H, Nookala VK, Cheriyath P. Prevalence of Vitamin D Deficiency and Associated Risk Factors in the US Population (2011-2012). Cureus. 2018 Jun 5;10(6):e2741. doi: 10.7759/cureus.2741.
    Results Reference
    background
    PubMed Identifier
    15671237
    Citation
    Hanley DA, Davison KS. Vitamin D insufficiency in North America. J Nutr. 2005 Feb;135(2):332-7. doi: 10.1093/jn/135.2.332.
    Results Reference
    background
    PubMed Identifier
    19957164
    Citation
    Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock J, Giovannucci E, Willett WC. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int. 2010 Jul;21(7):1121-32. doi: 10.1007/s00198-009-1119-3. Epub 2009 Dec 3.
    Results Reference
    background
    PubMed Identifier
    24953955
    Citation
    Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Krstic G, Wetterslev J, Gluud C. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev. 2014 Jun 23;(6):CD007469. doi: 10.1002/14651858.CD007469.pub2.
    Results Reference
    background
    PubMed Identifier
    24729336
    Citation
    Avenell A, Mak JC, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev. 2014 Apr 14;2014(4):CD000227. doi: 10.1002/14651858.CD000227.pub4.
    Results Reference
    background
    PubMed Identifier
    27604776
    Citation
    Malihi Z, Wu Z, Stewart AW, Lawes CM, Scragg R. Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: a systematic review and meta-analysis. Am J Clin Nutr. 2016 Oct;104(4):1039-1051. doi: 10.3945/ajcn.116.134981. Epub 2016 Sep 7.
    Results Reference
    background
    PubMed Identifier
    25495429
    Citation
    Reid IR. Efficacy, effectiveness and side effects of medications used to prevent fractures. J Intern Med. 2015 Jun;277(6):690-706. doi: 10.1111/joim.12339. Erratum In: J Intern Med. 2015 Sep;278(3):333.
    Results Reference
    background
    PubMed Identifier
    16507374
    Citation
    Brazier M, Grados F, Kamel S, Mathieu M, Morel A, Maamer M, Sebert JL, Fardellone P. Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2005 Dec;27(12):1885-93. doi: 10.1016/j.clinthera.2005.12.010.
    Results Reference
    background
    PubMed Identifier
    22139587
    Citation
    Lewis JR, Zhu K, Prince RL. Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation. J Bone Miner Res. 2012 Mar;27(3):719-22. doi: 10.1002/jbmr.1484.
    Results Reference
    background
    PubMed Identifier
    21646368
    Citation
    Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. doi: 10.1210/jc.2011-0385. Epub 2011 Jun 6. Erratum In: J Clin Endocrinol Metab. 2011 Dec;96(12):3908.
    Results Reference
    background
    PubMed Identifier
    18689406
    Citation
    Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008 Aug;88(2):582S-586S. doi: 10.1093/ajcn/88.2.582S.
    Results Reference
    background
    PubMed Identifier
    24937025
    Citation
    Gallagher JC, Smith LM, Yalamanchili V. Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women. Menopause. 2014 Nov;21(11):1173-80. doi: 10.1097/GME.0000000000000270.
    Results Reference
    background
    PubMed Identifier
    18390493
    Citation
    Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE, Kirsch I, Schyner RN, Nam BH, Nguyen LT, Park M, Rivers AL, McManus C, Kokkotou E, Drossman DA, Goldman P, Lembo AJ. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ. 2008 May 3;336(7651):999-1003. doi: 10.1136/bmj.39524.439618.25. Epub 2008 Apr 3.
    Results Reference
    background
    PubMed Identifier
    20091554
    Citation
    Hrobjartsson A, Gotzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD003974. doi: 10.1002/14651858.CD003974.pub3.
    Results Reference
    background
    PubMed Identifier
    9734904
    Citation
    Kaptchuk TJ. Powerful placebo: the dark side of the randomised controlled trial. Lancet. 1998 Jun 6;351(9117):1722-5. doi: 10.1016/S0140-6736(97)10111-8. No abstract available.
    Results Reference
    background
    PubMed Identifier
    18463276
    Citation
    Miller FG, Kaptchuk TJ. The power of context: reconceptualizing the placebo effect. J R Soc Med. 2008 May;101(5):222-5. doi: 10.1258/jrsm.2008.070466. No abstract available.
    Results Reference
    background
    PubMed Identifier
    12007544
    Citation
    Hrobjartsson A. What are the main methodological problems in the estimation of placebo effects? J Clin Epidemiol. 2002 May;55(5):430-5. doi: 10.1016/s0895-4356(01)00496-6.
    Results Reference
    background
    PubMed Identifier
    31959942
    Citation
    Amrein K, Scherkl M, Hoffmann M, Neuwersch-Sommeregger S, Kostenberger M, Tmava Berisha A, Martucci G, Pilz S, Malle O. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr. 2020 Nov;74(11):1498-1513. doi: 10.1038/s41430-020-0558-y. Epub 2020 Jan 20.
    Results Reference
    background
    PubMed Identifier
    19858440
    Citation
    Pietras SM, Obayan BK, Cai MH, Holick MF. Vitamin D2 treatment for vitamin D deficiency and insufficiency for up to 6 years. Arch Intern Med. 2009 Oct 26;169(19):1806-8. doi: 10.1001/archinternmed.2009.361. No abstract available.
    Results Reference
    background

    Learn more about this trial

    Clinical Trial of Vit D and Calcium for Recurrent BPPV

    We'll reach out to this number within 24 hrs